The researchers constructed a high-resolution single-cell atlas from more than 240,000 cells obtained from patients with gastric cancer. Single-cell RNA sequencing enabled them to examine gene-expression programs in individual cells rather than averaging signals across entire tumor samples. This approach revealed extensive cellular diversity within the tumor microenvironment, including multiple macrophage populations, T-cell states and metabolic programs associated with treatment response. Instead of finding that one immune cell type alone predicted outcome, the investigators identified a functional relationship between two macrophage states characterized by high expression of CXCL10 and OLR1.

Macrophages are adaptable immune cells that can respond to signals from cancer cells, stromal tissue and other immune populations. In the gastric tumors examined in the study, Mac-CXCL10 and Mac-OLR1 represented distinct functional states. The relative abundance of these populations was more informative than the simple presence or absence of either one. Tumors with a higher Mac-CXCL10/Mac-OLR1 ratio were more likely to respond to ICB therapy and were associated with longer progression-free survival. This ratio therefore emerged as a potential indicator of the immune conditions that make a tumor more receptive to checkpoint blockade.

The favorable macrophage state was closely linked to a population of interferon-responsive CD8-positive T cells. Interferons are signaling proteins that help coordinate antiviral and antitumor immunity by regulating antigen presentation, immune-cell recruitment and cytotoxic activity. The study suggests that Mac-CXCL10 cells and interferon-responsive CD8-positive T cells form a coordinated “interferon-responsive immune hub” within the tumor microenvironment. In this setting, macrophage-derived signals may help sustain T-cell activation, while activated T cells reinforce an inflammatory circuit capable of supporting tumor-cell recognition and destruction.

The opposing Mac-OLR1 state was associated with lipid-related metabolic programs and features of immune suppression. OLR1, also known as the lectin-like oxidized low-density lipoprotein receptor-1, can bind oxidized lipid particles and is involved in cellular responses to lipid stress. The findings indicate that the accumulation of oxidized lipids in the tumor environment may contribute to the development or maintenance of this macrophage population. Such metabolic pressure could alter macrophage gene expression and behavior, shifting the immune ecosystem away from effective T-cell stimulation.

A central mechanism identified by the researchers involved prostaglandin E₂, or PGE₂, a lipid-derived signaling molecule with broad effects on inflammation and immunity. Mac-OLR1 macrophages were linked to increased PGE₂-related activity. PGE₂ can influence immune-cell migration, cytokine production and T-cell function through signaling pathways that regulate intracellular cyclic AMP and downstream transcriptional responses. In the context of this study, PGE₂ was associated with suppression of interferon signaling in CD8-positive T cells, potentially weakening the production of effector molecules and reducing the ability of these cells to attack malignant cells.

This macrophage–T-cell relationship offers a possible explanation for why some gastric tumors fail to respond even when immune checkpoint molecules are therapeutically blocked. ICB can remove inhibitory signals such as those mediated by PD-1 or related pathways, but this intervention may be insufficient if the surrounding tissue continues to deliver metabolic and inflammatory signals that disable T cells. A PGE₂-rich environment could therefore act as an additional layer of immune resistance, limiting the restoration of T-cell activity after checkpoint inhibition.

The study also raises the possibility of combining immunotherapy with interventions aimed at the tumor’s lipid metabolism or PGE₂ signaling. Strategies that reduce oxidized-lipid stress, alter OLR1-associated macrophage programs or inhibit PGE₂ production and activity could, in principle, shift the macrophage balance toward a more immune-supportive state. Such approaches might enhance the effect of checkpoint blockade, although the study does not establish a treatment regimen for patients. The safety, timing and selectivity of any macrophage- or PGE₂-targeted therapy will require careful evaluation, since these pathways also participate in normal tissue repair and inflammatory control.

The investigators emphasize that their findings require further clinical validation before the macrophage ratio can be used as a routine biomarker. Nevertheless, the work provides a detailed framework for understanding gastric cancer immunotherapy resistance as an ecosystem-level problem. The outcome of treatment may depend not simply on whether immune cells are present, but on how macrophage states, lipid metabolism and T-cell interferon signaling interact within individual tumors. By identifying the Mac-CXCL10/Mac-OLR1 balance and its connection to PGE₂-mediated suppression, the study points toward a more precise form of immunotherapy in which the immune environment itself becomes a therapeutic target.

Subject of Research:
Macrophage states, tumor microenvironment, CD8⁺ T-cell immunity and immunotherapy response in gastric cancer.

Web References:
https://doi.org/10.1016/j.scib.2026.07.049

References:
Science Bulletin, DOI: 10.1016/j.scib.2026.07.049

Image Credits:
© Science Bulletin; created with BioRender.com.

Keywords:
Gastric cancer, immunotherapy, immune checkpoint blockade, tumor microenvironment, macrophages, CXCL10, OLR1, CD8⁺ T cells, interferon signaling, prostaglandin E₂, oxidized lipids, immunosuppression, single-cell atlas.

Hepatocellular carcinoma remains a formidable disease worldwide, characterized by poor prognosis and limited responsiveness to conventional treatments. Immune checkpoint inhibitors, particularly those targeting the programmed death-1 (PD-1) receptor, have revolutionized oncology by reactivating the immune system’s ability to recognize and attack tumor cells. However, many HCC patients display intrinsic or acquired resistance to these therapies, revealing an urgent need to discover adjunct molecular targets that can overcome such resistance. The current study introduces VRK2 as a critical regulator in this context, shedding light on its function beyond traditional cellular signaling roles.

VRK2, part of the vaccinia-related kinase family, is a serine/threonine-protein kinase previously associated with nuclear envelope dynamics and stress responses. Its elevated expression in hepatocellular carcinoma had been noted but not comprehensively understood in terms of therapeutic targeting. The research team employed integrative analyses combining in vitro models, animal studies, and clinical samples to elucidate VRK2’s role in modulating tumor immunogenicity. Crucially, they demonstrated that VRK2 interacts with signaling pathways that stabilize MYC protein levels, maintaining tumor growth and immune resistance.

MYC, a potent transcription factor, is infamous for its role in driving tumorigenesis and orchestrating cancer cell metabolism, proliferation, and survival. Its overexpression correlates with aggressive cancer phenotypes and poor patient outcomes. The new findings present a compelling narrative that inhibiting VRK2 destabilizes MYC, consequently impairing its oncogenic utility. This destabilization triggers a cascade of cellular events that render the tumor microenvironment more amenable to immune attack, notably enhancing the efficacy of PD-1 blockade therapies.

Functionally, VRK2 inhibition leads to reduced MYC protein half-life, which was validated through ubiquitination assays revealing increased MYC proteasomal degradation when VRK2 activity is curtailed. The research further identified that VRK2 maintains MYC stability via phosphorylation events that protect MYC from degradation. Interrupting this protective mechanism thus undermines the tumor’s capacity to evade immune surveillance. This insight represents a significant conceptual leap, positioning VRK2 as a critical molecular switch in the immuno-oncological landscape of HCC.

By employing a combination of genetic knockdown approaches and small-molecule inhibitors specific to VRK2, the team observed marked reductions in tumor cell proliferation and enhanced susceptibility to cytotoxic T lymphocyte-mediated killing. Synergistic effects became evident when VRK2 inhibition was paired with anti-PD-1 antibodies, potentiating immune checkpoint blockade beyond the capabilities of monotherapy. These findings were substantiated in mouse xenograft models, where the dual treatment significantly suppressed tumor growth and prolonged survival compared to controls.

The study also delves into the tumor microenvironment alterations upon VRK2 targeting. The suppression of VRK2 not only affects tumor intrinsic pathways but also modulates immune cell infiltration and activation. Enhanced recruitment of CD8+ T cells and increased production of pro-inflammatory cytokines were documented, establishing a more favorable immunostimulatory milieu within the tumor. This dual action mechanistically ties intracellular kinase signaling with extracellular immune dynamics, underscoring VRK2’s paramount role as a therapeutic fulcrum.

Importantly, the clinical relevance of these findings was corroborated by analysis of patient-derived HCC samples. Elevated VRK2 expression correlated inversely with response rates to approved anti-PD-1 therapies, suggesting VRK2 expression as a potential biomarker for immunotherapy responsiveness. These preliminary correlations prompt the consideration of integrating VRK2 expression profiling in clinical decision-making to personalize treatment regimens in HCC patients, a step towards precision oncology.

Beyond the immediate application in hepatocellular carcinoma, this research invites broader implications for tumor types where MYC-driven oncogenesis and immunotherapy resistance coalesce. The modularity of VRK2’s regulation of MYC hints at a universal node that, if exploited, could unlock new combinatory strategies across cancer subtypes. Given the widespread pursuit of improved checkpoint inhibition therapies, VRK2 represents an exciting prospect for next-generation targeted drug development.

Technically, the study leveraged cutting-edge molecular biology techniques, including CRISPR-Cas9-mediated gene editing, quantitative proteomics, and high-resolution immunohistochemistry, to dissect intricate signaling networks. The rigorous experimental design ensured reproducibility and translational validity, setting a new benchmark for preclinical immuno-oncology research. Such meticulous characterization not only solidifies the foundational science but also paves the way for accelerated clinical trials and drug repurposing strategies.

The pharmacological landscape for VRK2 is relatively untapped, presenting the research community with a challenging yet enticing frontier. Design of selective VRK2 inhibitors with favorable pharmacokinetic profiles remains a priority to translate these laboratory observations into viable clinical interventions. Concurrently, the safety profile of VRK2 modulation needs thorough evaluation, as kinases are often pleiotropic with roles extending beyond cancer biology. Strategic targeting will thus necessitate a delicate balance to maximize therapeutic gain while minimizing off-target effects.

Furthermore, the interplay between VRK2 and the immune system emphasizes the importance of integrating immunomodulatory insights into the drug development pipeline. The potential for VRK2 inhibitors to act as immunotherapy adjuvants sparks hope for overcoming resistance mechanisms that have hindered the full potential of checkpoint inhibitors in HCC. Such breakthroughs epitomize the patient-centered approach that modern oncology strives to achieve by harnessing molecular vulnerabilities unique to each tumor.

While these findings mark a significant stride, the path to clinical application will require comprehensive trials to validate efficacy, optimize dosing regimens, and identify potential combinatory partners beyond PD-1 blockade. Additionally, unraveling the full spectrum of VRK2’s biological functions will continue to inform the design of rational therapeutics. Close collaboration between molecular biologists, immunologists, and clinical oncologists will be crucial to translate this promising basic science into improved survival rates for liver cancer patients.

This seminal work from Su, Liao, Mo, and colleagues stands as a paradigm of how targeting intracellular kinases can directly influence immune checkpoint therapy outcomes. By illuminating VRK2’s pivotal role in MYC stability and immune resistance, the researchers have charted a new course in hepatocellular carcinoma treatment. As the oncology community eagerly anticipates further developments, this study exemplifies the innovative spirit driving cancer research into an era of smarter, more effective immunotherapies.

In conclusion, the discovery that VRK2 inhibition sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy through MYC destabilization represents a compelling advance with far-reaching clinical implications. This work underscores the transformative potential of combinatory molecular and immune therapeutic strategies, offering new hope for patients suffering from one of the most lethal cancers. Future research will undoubtedly build upon these insights to harness VRK2 as a central node in the quest to conquer cancer through precision immunotherapy.

Subject of Research:
The research focuses on the molecular targeting of vaccinia-related kinase 2 (VRK2) to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma through mechanisms involving the destabilization of the MYC oncogene.

Article Title:
“VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization”

Article References:
Su, C., Liao, Z., Mo, J. et al. VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization. Nat Commun 16, 9027 (2025). https://doi.org/10.1038/s41467-025-64079-6

Image Credits:
AI Generated